Vivanza Biosciences Ltd (BSE: 530057) is an Ahmedabad, Gujarat-based company in the Medical Consumables industry. With a market capitalisation of ₹6 Cr, it ranks #4,966 by market cap among the 6,197 Indian listed companies on FinBizNet, and #13 of 14 in Medical Consumables. At ₹1.42 (as of 19 Nov 2026), the share price is 42.3% below its 52-week high of ₹2.46 and 9.2% above its 52-week low of ₹1.30. The share price is down 33.6% over one year and down 18.6% over three months.
| Current Price | ₹1.42 |
|---|---|
| Market Cap | ₹6 Cr |
| BSE Code | 530057 |
| Sector | Health Care > Health Care Equipment and Services > Health Care Equipment and Supplies |
| Sub-Industry | Health Care Supplies > Medical Consumables |
| P/E Ratio | 14.7 |
| Return on Equity | 9.48% |
| Return on Assets | 2.44% |
| 52-Week Range | ₹1.30 – ₹2.46 |
| 1-Year Price Change | -33.6% |
| 3-Month Price Change | -18.6% |
| Beta (1Y) | 0.35 |
| Headquarters | Ahmedabad, Gujarat |
| Website | vivanzabiosciences.com |
| Revenue | ₹9 Cr |
|---|---|
| Net Profit | ₹0 Cr |
| Net Margin | 1.6% |
| EPS (Basic) | ₹0.04 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Vivanza Biosciences Ltd reported revenue of ₹9 Cr in Q1 FY27, up 16.9% from ₹8 Cr in Q1 FY26 and up 59.0% from ₹6 Cr in Q4 FY26. It posted a net profit of ₹0 Cr for the quarter, against a net profit of ₹0 Cr in Q1 FY26 (up 650.0%). Across the 6 quarters from Q4 FY25 to Q1 FY27, quarterly revenue ranged from ₹0 Cr (Q4 FY25) to ₹54 Cr (Q2 FY26). The company reported a net loss in 2 of these 6 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q1 FY27 | ₹9 Cr | ₹0 Cr | 1.6% |
| Q4 FY26 | ₹6 Cr | −₹0 Cr | −4.7% |
| Q3 FY26 | ₹45 Cr | ₹0 Cr | 0.4% |
| Q2 FY26 | ₹54 Cr | ₹0 Cr | 0.9% |
| Q1 FY26 | ₹8 Cr | ₹0 Cr | 0.3% |
| Q4 FY25 | ₹0 Cr | −₹1 Cr | −570.6% |
Standalone figures (₹ crore, XBRL filings).
Delivery averaged 92.5% of traded volume across 16 BSE sessions (26 Oct 2026 – 19 Nov 2026).
Vivanza Biosciences Limited engages in the research, development, manufacture, and distribution of pharmaceutical products in India. It offers latex surgical and examination, and latex free examination gloves, as well as other surgical products. The company was incorporated in 1982 and is based in Ahmedabad, India.
1. Pharmaceuticals Related Activities-This segment engages in the trading of various pharmaceutical products.
1. Agro,Plastic Polymer Films and Pharmaceuticals Related Activities-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Poly Medicure Ltd. | ₹17,162 Cr | 53.3 | 10.84% | ₹581 Cr | -14.5% |
| Sahajanand Medical Technologies | ₹4,899 Cr | 77.9 | — | ₹373 Cr | — |
| Q-Line Biotech Limited | ₹1,280 Cr | 15.7 | 22.63% | — | — |
| Laxmi Dental Limited | ₹1,128 Cr | 39.3 | 12.77% | ₹80 Cr | -38.2% |
| Prevest Denpro Ltd | ₹502 Cr | 24.6 | 17.79% | — | -22.6% |
| Choksi Imaging Ltd. | ₹119 Cr | 22.3 | 13.51% | — | +94.0% |
| GSM Foils Limited | ₹72 Cr | 3.9 | 37.54% | ₹97 Cr | -78.3% |
| Mohini Health & Hygiene Ltd | ₹51 Cr | n/m | -17.18% | — | -41.2% |
| Vivanza Biosciences Ltd | ₹6 Cr | 14.7 | 9.48% | ₹9 Cr | -33.6% |
Listed by market capitalisation. Ratios are shown for context only.
Vivanza Biosciences Ltd is trading at ₹1.42, with a market capitalisation of ₹6 Cr.
Vivanza Biosciences Ltd operates in the Health Care > Health Care Equipment and Services > Health Care Equipment and Supplies space (Health Care Supplies > Medical Consumables).
Vivanza Biosciences Ltd has a P/E of 14.7 and a return on equity of 9.48%.
Vivanza Biosciences Ltd is listed on the BSE under the scrip code 530057.
Vivanza Biosciences Ltd's share price is down 33.6% over one year and down 18.6% over three months. Its 52-week range is ₹1.30 to ₹2.46.
In Q1 FY27, Vivanza Biosciences Ltd reported revenue of ₹9 Cr and net profit of ₹0 Cr, with basic EPS of ₹0.04 (standalone, parsed from the company's exchange filing).
Vivanza Biosciences Ltd reported revenue of ₹9 Cr in Q1 FY27, up 16.9% from ₹8 Cr in Q1 FY26 and up 59.0% from ₹6 Cr in Q4 FY26.
Data as of 19 Nov 2026. Descriptive market data only — not investment advice.